Design Therapeutics, Inc. (DSGN)
NASDAQ: DSGN · Real-Time Price · USD
9.77
-0.05 (-0.51%)
At close: Dec 5, 2025, 4:00 PM EST
9.96
+0.19 (1.94%)
After-hours: Dec 5, 2025, 7:14 PM EST
Design Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| Revenue | - | - | - | - | - | 0.23 | |
| Revenue Growth (YoY) | - | - | - | - | - | -72.90% | |
| Cost of Revenue | 57.86 | 44.35 | 57.06 | 48.61 | 24.78 | 6.06 | |
| Gross Profit | -57.86 | -44.35 | -57.06 | -48.61 | -24.78 | -5.83 | |
| Selling, General & Admin | 19.73 | 18.03 | 21.13 | 18.98 | 11.05 | 2.5 | |
| Operating Expenses | 19.73 | 18.03 | 21.13 | 18.98 | 11.05 | 2.5 | |
| Operating Income | -77.59 | -62.38 | -78.19 | -67.59 | -35.83 | -8.33 | |
| Interest & Investment Income | 10.55 | 12.8 | 11.33 | - | - | - | |
| Other Non Operating Income (Expenses) | - | - | - | 2.89 | 0.22 | -0.02 | |
| EBT Excluding Unusual Items | -67.05 | -49.59 | -66.86 | -64.7 | -35.61 | -8.35 | |
| Gain (Loss) on Sale of Investments | - | - | - | 1.4 | 0.08 | 0.07 | |
| Pretax Income | -67.45 | -49.59 | -66.86 | -63.31 | -35.53 | -8.28 | |
| Net Income | -67.45 | -49.59 | -66.86 | -63.31 | -35.53 | -8.28 | |
| Net Income to Common | -67.45 | -49.59 | -66.86 | -63.31 | -35.53 | -8.28 | |
| Shares Outstanding (Basic) | 57 | 57 | 56 | 56 | 46 | 16 | |
| Shares Outstanding (Diluted) | 57 | 57 | 56 | 56 | 46 | 16 | |
| Shares Change (YoY) | 0.66% | 1.08% | 0.50% | 21.27% | 190.80% | 2.08% | |
| EPS (Basic) | -1.19 | -0.88 | -1.19 | -1.14 | -0.77 | -0.52 | |
| EPS (Diluted) | -1.19 | -0.88 | -1.19 | -1.14 | -0.77 | -0.52 | |
| Free Cash Flow | -52.41 | -43.45 | -58.82 | -52.24 | -30.92 | -8.75 | |
| Free Cash Flow Per Share | -0.92 | -0.77 | -1.05 | -0.94 | -0.67 | -0.55 | |
| Operating Margin | - | - | - | - | - | -3685.84% | |
| Profit Margin | - | - | - | - | - | -3663.72% | |
| Free Cash Flow Margin | - | - | - | - | - | -3869.47% | |
| EBITDA | -76.98 | -61.79 | -77.65 | -67.19 | -35.7 | -8.33 | |
| D&A For EBITDA | 0.62 | 0.6 | 0.54 | 0.41 | 0.13 | 0.01 | |
| EBIT | -77.59 | -62.38 | -78.19 | -67.59 | -35.83 | -8.33 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.